-Reuters
Morgan Stanley Upgrades Regeneron Pharmaceuticals to Overweight, Raises Price Target to $851
Morgan Stanley analyst Matthew Harrison upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) from Equal-Weight to Overweight and raises the price target from $625 to $851.